I grew up on a steady diet of Star Trek. The portrayal of the modern medical clinic aboard the Enterprise was of particular interest to me, with such wonders as instant inoculations and vaccines, and biosensors that could provide readouts following a mere touch to the skin. Of course, this was pure science fiction, but in some ways, we are moving toward these fanciful ideas.

An example of this march to the future can be found in the collaboration between Vanderbilt University's Institute for Integrative Biosystems Research and Education (VIIBRE) and Pria Diagnostics, a privately held California company that specializes in miniaturized medical diagnostics. The agreement, announced late last year, aims to develop a portable device similar to today's home pregnancy tests that could quickly detect the presence of infectious diseases, including HIV and measles, as well as biological agents such as ricin and anthrax.

VIIBRE has developed special electrodes that have been customized to measure the concentrations of the metabolites that cells consume and excrete in extremely small volumes. It has also developed microfluidic devices that enable the electrodes to move and manipulate small numbers of cells reliably. Meanwhile, Pria has developed a micro-optical fluorescence spectroscopy system and used it as the basis for a portable male fertility detector that measures sperm motility with accuracy comparable to laboratory analyses. The device includes an optical MEMS component together with an LED to read fluorescent chemicals that bind to a sample of sperm. The groups plan to work together to prototype portable instruments for clinical diagnosis and biodefense.

continues after box

Call for Presentations:   2005 Bio-IT World Venture Forum The application deadline is February 25, 2005. One of the highlights of the upcoming Bio-IT World Conference + Expo (May 17-19, 2005) will be the Venture Forum, hosted by Ernst & Young and IDG Ventures. This program will include industry overviews from Bryan Pearce (Ernst & Young) and Jim Golden (SAIC), and a panel of leading technology buyers from some of the most prestigious biopharma organizations. The organizers of this year's Venture Forum are inviting applications to present at the Forum from young bio-IT/biopharma technology providers. If you: represent an exciting young company in areas including, but not limited to, software, grid computing, and instrumentation; are seeking to raise $2-$20 million in the next one to two years; and would like the opportunity to showcase your organization and expertise at the 2005 Venture Forum, please download the application or contact: Kate Greene, IDG World Expo, Ph: 508-424-4815, Email: kate_greene@idg.com.

continued

Treating AIDS patients is expensive, and healthcare professionals have the problem of deciding when to start and stop anti-retroviral therapy. According to CTO Jason Pyle, Pria is developing a device that it hopes will allow medical professionals and HIV patients to manage the disease in a way similar to how diabetes patients monitor their condition with home blood-glucose detectors. A goal of the collaboration is to produce the first portable HIV monitor within two years.

A key VIIBRE technology is an electrode-based sensor capable of simultaneously measuring the concentrations of key chemicals and metabolites that cells consume and excrete -- oxygen, glucose, and lactic acid -- with sufficient sensitivity to monitor the health of a few thousand cells. Called a four-channel microphysiometer, the device is a modification of Molecular Devices' decade-old Cytosensor, which was designed to measure changes in acidity in a small chamber holding 100,000 to 1,000,000 cultured cells. The VIIBRE group added three additional sensors, allowing the device to simultaneously chart variations in the concentrations of oxygen, glucose, and lactic acid, in addition to pH, in real time. Described in an article last year in Analytical Chemistry (76, 519-27; 2004), the added capability is important because monitoring variations in these four parameters allow researchers to quickly assess the impact that exposure to different chemicals has on the metabolic activity and health of small groups of cells.

Vanderbilt researchers have recently further miniaturized the customized sensors to record rapid changes in the metabolism and signaling of individual cells. To handle such small numbers of cells, they adapted a method for molding microchannels and valves from a plastic similar to that used in soft contact lenses. This has given them the capability to capture, manipulate, grow, and study single living cells in volumes that are barely larger than the cells themselves.

While most sensors identify a single toxic agent or group of agents, the ability to monitor the health of small groups of cells makes it possible to detect the presence of unknown poisons as long as they affect cell metabolism. Furthermore, by examining the impact

an unknown agent has on different cell types the approach may provide insights into its mode of toxicity. The device may also find application as a high-throughput screening system to determine the biological activity of large numbers of compounds.

Clearly not science fiction, but devices that might have come in handy while exploring new worlds!

Robert M. Frederickson is a science writer based in Seattle. E-mail: rfreder@yahoo.com.

Comprehensive Fractionation

QIAGEN has developed the QProteome product line, which according to the company represents one of the most comprehensive and technologically advanced solution portfolios for the fractionation of proteins. The QProteome kits provide reagents, buffers, and consumable column and bead formats that leverage novel and proprietary separation technologies and is designed to reduce the complexity of the proteome and/or fractionate complex protein samples for subsequent analysis. This allows researchers to separate, purify, and characterize lower-abundance proteins from complex proteomes. The kits work by separating proteins by glycosylation patterns, their subcellular localization, their affinity to nuclei acids, or their overall solubility. The QProteome kits can also be used to localize or characterize biomarkers in cells grown under different conditions or isolated from different tissues.

Vendor: QIAGEN

Product: QProteome kits

Availability: Now

For more information: 800-362-7737 www.qiagen.com

The Peak of Separations

ZirChrom Separations is offering next generation carbon-based high performance liquid chromatography (HPLC) columns, which provide enhanced features for powerful method development. It has enhanced retention and very different selectivity for most compounds compared to bonded phase C18 silica; improved peak shape and efficiency; and is compatible with conventional mobile phase buffers. The company says the ZirChrom SELECT, which uses the company's novel covalently attached Lewis acid deactivation chemistry, is the first carbon-based HPLC column to deliver acceptable peak shape for a wide variety of pharmaceutically-relevant compounds, and is able to distinguish zirconia-based columns from traditional bonded C18 silica phases.

Vendor: ZirChrom Separations

Product: ZirChrom SELECT chromatography columns

Availability: Now

For more information: 866-STABLE-1 www.zirchrom.com

SPOTCHEM Spots Segment

Polymedco has introduced a new, FDA-approved, automated dry chemistry analyzer to their expanding portfolio of diagnostic equipment. The SPOTCHEM EZ Analyzer is a compact system that provides physicians with the ability to perform routine chemistry testing in their own laboratory rather then sending it out to a reference lab. The company says the SPOTCHEM EZ fits a segment of the market that is in need of such an instrument because many labs are not large enough to support a full size chemistry instrument. SPOTCHEM EZ eliminates costly waste by utilizing stable test strips rather than liquid reagents and is electronically calibrated for ease of use. Doctors will have the ability to run multiple tests simultaneously, reducing the time necessary to process patient results.

Vendor: Polymedco

Product: SPOTCHEM EZ Analyzer

Availability: Now

For more information: 800-431-2123  www.polymedco.com

Versatility in Variables

Quinton Cardiology Systems in partnership with the University of Glasgow in Scotland has developed the software for the Atria 3000, an electrocardiogram (ECG) recorder that features the University of Glasgow's ECG Interpretation Algorithm that combines cutting-edge capabilities, such as wireless communications, within a traditional ECG recorder. The software uses five clinically significant variables - gender, age, race, medication, and clinical history in addition to ECG measurements when making an interpretation of a patient's ECG, which is critical as ECG patterns for patients from different ethnic backgrounds and with different medical conditions can vary greatly.

Vendor: Quinton Cardiology Systems

Product: Atria 3000 software

Availability: Now

For more information: 800-426-0337  www.quinton.com